Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma

Suguru Shirotake, Kimiharu Takamatsu, Ryuichi Mizuno, Go Kaneko, Koshiro Nishimoto, Mototsugu Oya, Masafumi Oyama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aim: The purpose of this retrospective study was to identify the predictive biomarkers of response to pretreatment for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Materials and Methods: The subjects were 54 patients treated with nivolumab for mRCC with a clear cell component (mccRCC) between September 2016 and February 2018. We analyzed the impact of serum biomarkers (lactate dehydrogenase [LDH], neutrophil–to–lymphocyte ratio, and C-reactive protein) on patients treated with nivolumab. We adopted the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model using six clinical factors (0=favorable, 1 or 2=intermediate, 3 to 6=poor risk groups, respectively). Results: The prognostic risk classification (non-poor vs. poor) and serum LDH levels were correlated with the objective response of nivolumab treatment for mccRCC. Elevated serum LDH levels at baseline were an independent biomarker for progression-free survival (PFS) of mccRCC patients receiving nivolumab [HR=2.268 (95%CI=1.014-5.051), p=0.046]. Notably, high LDH levels were associated with a poorer PFS for patients in the favorable-risk group. Conclusion: Serum LDH levels at baseline before nivolumab treatment were associated with the objective response and clinical outcome of nivolumab treatment.

Original languageEnglish
Pages (from-to)4371-4377
Number of pages7
JournalAnticancer research
Volume39
Issue number8
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

L-Lactate Dehydrogenase
Biomarkers
Serum
Cellular Structures
Renal Cell Carcinoma
Therapeutics
Disease-Free Survival
nivolumab
Clear-cell metastatic renal cell carcinoma
C-Reactive Protein
Retrospective Studies
Databases

Keywords

  • Lactate dehydrogenase
  • Nivolumab
  • Outcome
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma. / Shirotake, Suguru; Takamatsu, Kimiharu; Mizuno, Ryuichi; Kaneko, Go; Nishimoto, Koshiro; Oya, Mototsugu; Oyama, Masafumi.

In: Anticancer research, Vol. 39, No. 8, 01.01.2019, p. 4371-4377.

Research output: Contribution to journalArticle

@article{486374d318d34deca6b16ada6b8cbe74,
title = "Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma",
abstract = "Background/Aim: The purpose of this retrospective study was to identify the predictive biomarkers of response to pretreatment for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Materials and Methods: The subjects were 54 patients treated with nivolumab for mRCC with a clear cell component (mccRCC) between September 2016 and February 2018. We analyzed the impact of serum biomarkers (lactate dehydrogenase [LDH], neutrophil–to–lymphocyte ratio, and C-reactive protein) on patients treated with nivolumab. We adopted the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model using six clinical factors (0=favorable, 1 or 2=intermediate, 3 to 6=poor risk groups, respectively). Results: The prognostic risk classification (non-poor vs. poor) and serum LDH levels were correlated with the objective response of nivolumab treatment for mccRCC. Elevated serum LDH levels at baseline were an independent biomarker for progression-free survival (PFS) of mccRCC patients receiving nivolumab [HR=2.268 (95{\%}CI=1.014-5.051), p=0.046]. Notably, high LDH levels were associated with a poorer PFS for patients in the favorable-risk group. Conclusion: Serum LDH levels at baseline before nivolumab treatment were associated with the objective response and clinical outcome of nivolumab treatment.",
keywords = "Lactate dehydrogenase, Nivolumab, Outcome, Renal cell carcinoma",
author = "Suguru Shirotake and Kimiharu Takamatsu and Ryuichi Mizuno and Go Kaneko and Koshiro Nishimoto and Mototsugu Oya and Masafumi Oyama",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13606",
language = "English",
volume = "39",
pages = "4371--4377",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma

AU - Shirotake, Suguru

AU - Takamatsu, Kimiharu

AU - Mizuno, Ryuichi

AU - Kaneko, Go

AU - Nishimoto, Koshiro

AU - Oya, Mototsugu

AU - Oyama, Masafumi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: The purpose of this retrospective study was to identify the predictive biomarkers of response to pretreatment for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Materials and Methods: The subjects were 54 patients treated with nivolumab for mRCC with a clear cell component (mccRCC) between September 2016 and February 2018. We analyzed the impact of serum biomarkers (lactate dehydrogenase [LDH], neutrophil–to–lymphocyte ratio, and C-reactive protein) on patients treated with nivolumab. We adopted the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model using six clinical factors (0=favorable, 1 or 2=intermediate, 3 to 6=poor risk groups, respectively). Results: The prognostic risk classification (non-poor vs. poor) and serum LDH levels were correlated with the objective response of nivolumab treatment for mccRCC. Elevated serum LDH levels at baseline were an independent biomarker for progression-free survival (PFS) of mccRCC patients receiving nivolumab [HR=2.268 (95%CI=1.014-5.051), p=0.046]. Notably, high LDH levels were associated with a poorer PFS for patients in the favorable-risk group. Conclusion: Serum LDH levels at baseline before nivolumab treatment were associated with the objective response and clinical outcome of nivolumab treatment.

AB - Background/Aim: The purpose of this retrospective study was to identify the predictive biomarkers of response to pretreatment for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Materials and Methods: The subjects were 54 patients treated with nivolumab for mRCC with a clear cell component (mccRCC) between September 2016 and February 2018. We analyzed the impact of serum biomarkers (lactate dehydrogenase [LDH], neutrophil–to–lymphocyte ratio, and C-reactive protein) on patients treated with nivolumab. We adopted the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model using six clinical factors (0=favorable, 1 or 2=intermediate, 3 to 6=poor risk groups, respectively). Results: The prognostic risk classification (non-poor vs. poor) and serum LDH levels were correlated with the objective response of nivolumab treatment for mccRCC. Elevated serum LDH levels at baseline were an independent biomarker for progression-free survival (PFS) of mccRCC patients receiving nivolumab [HR=2.268 (95%CI=1.014-5.051), p=0.046]. Notably, high LDH levels were associated with a poorer PFS for patients in the favorable-risk group. Conclusion: Serum LDH levels at baseline before nivolumab treatment were associated with the objective response and clinical outcome of nivolumab treatment.

KW - Lactate dehydrogenase

KW - Nivolumab

KW - Outcome

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85070690246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070690246&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13606

DO - 10.21873/anticanres.13606

M3 - Article

C2 - 31366532

AN - SCOPUS:85070690246

VL - 39

SP - 4371

EP - 4377

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -